EQL Pharma AB (publ) (STO:EQL)
Sweden
· Delayed Price · Currency is SEK 83.80
+1.00 (1.21%)
At close: Feb 21, 2025
EQL Pharma AB Income Statement
Financials in millions SEK. Fiscal year is April - March.
Millions SEK. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
| Operating Revenue | 338.39 | 264.17 | 259.91 | 409.75 | 179.14 | 72.03 | Upgrade
|
| Other Revenue | - | - | - | - | - | 0 | Upgrade
|
| Revenue | 338.39 | 264.17 | 259.91 | 409.75 | 179.14 | 72.03 | Upgrade
|
| Revenue Growth (YoY) | 37.35% | 1.64% | -36.57% | 128.73% | 148.70% | 44.77% | Upgrade
|
| Cost of Revenue | 197.5 | 149.12 | 144.06 | 314.02 | 128.14 | 35.21 | Upgrade
|
| Gross Profit | 140.9 | 115.05 | 115.85 | 95.73 | 51.01 | 36.82 | Upgrade
|
| Selling, General & Admin | 77.51 | 70.8 | 59.79 | 48.16 | 28.3 | 29.99 | Upgrade
|
| Research & Development | 11.76 | 12.09 | 15.14 | 9.13 | 11.7 | - | Upgrade
|
| Other Operating Expenses | -1.14 | -0.46 | -0.41 | -0.4 | -0.51 | -0.46 | Upgrade
|
| Operating Expenses | 88.13 | 82.43 | 74.51 | 56.9 | 39.48 | 32.29 | Upgrade
|
| Operating Income | 52.77 | 32.62 | 41.34 | 38.84 | 11.52 | 4.53 | Upgrade
|
| Interest Expense | -8.99 | -5.73 | -2.37 | -2.87 | -1.1 | -0.43 | Upgrade
|
| Interest & Investment Income | 0.2 | 0.2 | 0 | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | -1.72 | -0 | - | 0 | - | - | Upgrade
|
| EBT Excluding Unusual Items | 42.25 | 27.08 | 38.97 | 35.97 | 10.42 | 4.1 | Upgrade
|
| Gain (Loss) on Sale of Investments | 1.53 | 1.53 | - | - | - | - | Upgrade
|
| Asset Writedown | - | - | - | - | - | -1.38 | Upgrade
|
| Pretax Income | 43.78 | 28.6 | 38.97 | 35.97 | 10.42 | 2.72 | Upgrade
|
| Income Tax Expense | 9.05 | 5.9 | 8.05 | 4.42 | 0.06 | 0.02 | Upgrade
|
| Net Income | 34.73 | 22.71 | 30.92 | 31.55 | 10.37 | 2.71 | Upgrade
|
| Net Income to Common | 34.73 | 22.71 | 30.92 | 31.55 | 10.37 | 2.71 | Upgrade
|
| Net Income Growth | 56.89% | -26.57% | -1.99% | 204.32% | 282.97% | - | Upgrade
|
| Shares Outstanding (Basic) | 29 | 29 | 29 | 29 | 29 | 30 | Upgrade
|
| Shares Outstanding (Diluted) | 29 | 29 | 30 | 29 | 29 | 30 | Upgrade
|
| Shares Change (YoY) | -1.74% | -1.56% | 1.59% | - | -3.37% | -0.60% | Upgrade
|
| EPS (Basic) | 1.19 | 0.78 | 1.06 | 1.09 | 0.36 | 0.09 | Upgrade
|
| EPS (Diluted) | 1.19 | 0.78 | 1.04 | 1.09 | 0.36 | 0.09 | Upgrade
|
| EPS Growth | 61.03% | -25.00% | -4.19% | 204.32% | 296.33% | - | Upgrade
|
| Free Cash Flow | -14.64 | -12.36 | 27.16 | 41.2 | 59.64 | 6.19 | Upgrade
|
| Free Cash Flow Per Share | -0.50 | -0.43 | 0.92 | 1.42 | 2.05 | 0.21 | Upgrade
|
| Gross Margin | 41.64% | 43.55% | 44.57% | 23.36% | 28.47% | 51.12% | Upgrade
|
| Operating Margin | 15.59% | 12.35% | 15.90% | 9.48% | 6.43% | 6.29% | Upgrade
|
| Profit Margin | 10.26% | 8.59% | 11.90% | 7.70% | 5.79% | 3.76% | Upgrade
|
| Free Cash Flow Margin | -4.33% | -4.68% | 10.45% | 10.06% | 33.29% | 8.59% | Upgrade
|
| EBITDA | 59.08 | 38.81 | 47.37 | 40.54 | 16.57 | 6.95 | Upgrade
|
| EBITDA Margin | 17.46% | 14.69% | 18.23% | 9.89% | 9.25% | 9.65% | Upgrade
|
| D&A For EBITDA | 6.31 | 6.19 | 6.03 | 1.7 | 5.05 | 2.42 | Upgrade
|
| EBIT | 52.77 | 32.62 | 41.34 | 38.84 | 11.52 | 4.53 | Upgrade
|
| EBIT Margin | 15.59% | 12.35% | 15.90% | 9.48% | 6.43% | 6.29% | Upgrade
|
| Effective Tax Rate | 20.68% | 20.62% | 20.65% | 12.28% | 0.53% | 0.62% | Upgrade
|
| Revenue as Reported | - | - | - | - | - | 72.49 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.